Filter
37
Text search:
protein-based
Featured
4
2
Language
Document type
18
6
5
4
3
1
Countries / Regions
2
2
1
1
1
1
Authors & Publishers
Publication Years
Category
4
3
2
2
1
1
Toolboxes
18
2
2
2
1
1
1
1
1
1
1
1
1
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.
Научная справка
8 апреля 2020 г.
В ответ на растущую пандемию COVID-19 и нехватку ресурсов и реагентов для молекулярного тестирования, многие производители диагностич
...
Научная справка
24 апреля 2020 г.
При инфицировании в естественных условиях выработка иммунитета к патогенному микроорганизму проходит в несколько этапов и заним
...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Humanitarian emergencies, regardless of type and cause, have a number of common risk factors for communicable diseases inextricably linked to excess risk of morbidity and mortality which can come from vaccine–preventable diseases (VPDs). The reduction of VPDs is a significant aim of public-health
...
Nota científica
24 de abril de 2020
El desarrollo de inmunidad a un patógeno por infección natural es un proceso de varias etapas que suele producirse a lo largo de una o dos semanas. El organismo responde a una infección vírica de forma inmediata a través de una respuesta innata no específ
...
Document d’information scientifique
24 avril 2020
Le développement d’une immunité face à un agent pathogène à la suite d’une infection naturelle comporte plusieurs étapes et prend généralement une à deux semaines. Une infection virale entraîne immédiatement une réponse immunit
...
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th
...
first issued 18 August 2022
This guide provides a comprehensive overview of essential information related to immunization, including technical information about vaccines, a review of immunization program management best practices, guidance on the delivery of immunization services, monitoring and evaluation, disease surveillanc
...
The WHO laboratory biosecurity guidance follows and complements the revision of the Laboratory biosafety manual, fourth edition and provides principles and measures to prevent lapses and incidents throughout the whole value chain of handling high-consequence biological material, technology and infor
...
19 February 2018
Scientific brief
8 April 2020
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir
...
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced.
For ease of use, the man
...
